Τόμος 14 (2000) – Τεύχος 1 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 14 (2000) – Issue 1 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Molecular Endocrinology Program, Institute of Biological Research and Biotechnology, the National Hellenic Research Foundation, Athens, Greece

Accepted for publication: 5 December 1999

pharmakonpress[at]pharmakonpress[.]gr

2.    Wakeling A.E.: The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res. Treat. 25: 1-9 (1993)

3.    Davidson N.E., Lippman M.E.: The role of estrogens in growth regulation of breast cancer. Crit. Rev. Oncog. 1: 89-111 (1989)

4.    Ettinger B.: Overview of estrogen replacement therapy: a historical perspective. Proc. Soc. Exp. Biol. Med. 217: 2- 5 (1998)

5.    Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., Cummings S.R.: Estrogen replacement therapy and fractures In older women. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 122: 9-16 (1995)

6.    Nasr A., Breckwoldt M.: Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg. Gynecol. Endocrinol. 12: 43-59 (1998)

7.    Yaffe K., Sawaya G., Lieberburg l., Grady D.: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279: 688-695 (1998)

8.    Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350: 1047- 1059 (1997)

9.    Beresford S.A., Weiss N.S., Voigt L.F., Mcknight B.: Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349: 458-461 (1997)

10.  Hayes D.F., Van Zyl J.A., Hacking A., Goedhals L.t Bezwoda W.R., Mailliard J.A., Jones S.E., Vogel C.L., Berris R.F., Shemano I., et al.: Randomized comparison of tamoxifen and two separate doses of toremifene in post-menopausal patients with metastatic breast cancer. J. Clin. Oncol. 13: 2556-2566 (1995)

11.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351: 1451-1467 (1998)

12.  Osborne C.K.: Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339: 1609-1618 (1998)

13.  Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90: 1371- 1388 (1998)

14.  Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M.: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86: 527-537(1994)

15.  Tomas E., Kauppila A., Blanco G.t Apaja-Sarkkinen M., Laatikainen T.: Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol. Oncol. 59: 261-266 (1995)

16.  Grey A.B., Stapleton J.P., Evans M.C., Tatnell M.A., Ames R.W., Reid I.R.: The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am. J. Med. 99: 636-641 (1995)

17.  Powles T.J., Hickish T., Kants J.A., Tidy A., Ashley S.: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 14: 78-84 (1996)

18.  Rauschning W., Pritchard K.I.: Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res. Treat. 31: 83-94 (1994)

19.  Ke H.Z., Simmons H.A., Pirîe C.M., Crawford D.T., Thompson D.D.: Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136: 2435-2441 (1995)

20.  MacGregor J.I., Jordan V.C.: Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50: 151-196 (1998)

21.  Howell A., Robertson J.: Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345: 989-990 (1995)

22.  Howell A., DeFriend D.J., Robert son J.F., Blarney R.W., Anderson L., Anderson E., Sutcliffe F.A., Walton P.: Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br. J. Cancer 74: 300-308 (1996)

23.  Grese T.A., Pennington L.D., Sluka J.P., Adrian M.D., Cole H.W., Fuson T.R., Magee D.E., Phillips D.L., Rowley E.R., Shetler P.K., Short L.L., Venugopalan M., Yang N.N., Sato M., Glasebrook A.L., Bryant H.U.: Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators, J. Med. Chem. 41: 1272-1283 (1998)

24.  Sato M., Zeng G.Q., Rowley E., Turner C.H.: LY353381 x HCI: an improved benzothiophene analog with bone-efficacy complementary to parathyroid hormone (1- 34). Endocrinology 139: 4642-4651 (1998)

25.  Buzdar A.U., Marcus C., Holmes F., Hug V., Hortobagyi G.: Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45: 344-345 (1988)

26.  Jordan V.C., Morrow M.: Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr. Rev, 20: 253-278 1999

27.  Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., Christiansen C.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in post-menopausal women. N. Engl. J. Med. 337: 1641-1647 (1997)

28.  Clarkson T.B., Anthony M.S., Jerome C.P.: Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 83: 721-726 (1998)

29.  Bryant H.U., Kauffman R.F., Iversen P., Cox D.A., Mitlak B.H., Heath H. 3rd: Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 83: 3001- 3004 (1998)

30.  Martel C, Labrie C, Belanger A, Gauthier S, Merand Y, U X, Provencher L, Candas B, Labrie F: Comparison of the effects of the new orally active antiestrogen EM-800 with l Cl 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology 133: 2486-2492 (1998)

31.  Labrie F., Labrie C., Belanger A., Simard J., Gauthier S., Luu-The V., Merand Y., Giguere V., Candas 8., Luo S., Martel C., Singh S.M., Fournier M., Coquet A., Richard V., Charbonneau R., Charpenet G., Tremblay A., Tremblay G., Cusan L., Veiileux R.: EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol. 63: 51-84 (1999)

32.  Green S., Walter P., Kumar V., Krust A., Bornert J.M., Argos P., Chambon P.: Human oestrogen receptor cDNA: sequence, expression and homology to verb-A. Nature 320: 134-139 (1986)

33.  Greene G.L., Giina P., Waterfield M., Baker A., Hort Y., Shine J.: Sequence and expression of human estrogen receptor complementary DNA. Science 231: 1150-1154 (1986)

34.  Moore J.T., McKee D.D., Slentz-Kesler K„ Moore L.B., Jones S.A., Horne E.L, Su J.L, Kliewer S.A., Lehmann J.M., Willson T.M.: Cloning and characterization of human estrogen receptor beta isoforms. Biochem. Biophys. Res. Commun. 247: 75-78 (1998)

35.  Ogawa S., Inoue S., Watanabe T., Hiroi H., Orimo A., Hosoi T., Ouchi Y., Muramatsu M.: The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem. Biophys. Res. Commun. 243: 122-126(1998)

36.  Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H., et al.: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494 (1995)

37.  Bunone G., Briand P.A., Miksicek R.J., Picard D.: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBOJ. 15: 2174-2183 (1996)

38.  Ignar-Trowbridge D.M., Pimentel M., Parker M.G., McLachlan J.A., Korach K.S.: Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137: 1735-1744 (1996)

39.  Tremblay A., Tremblay G.B., Labrie F., Giguere V.: Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol. Cell. 3: 513-519 (1999)

40.  Bocchinfuso W.P., Hively W.P., Couse J.F., Varmus H.E., Korach K.S.: A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res. 53: 1869-1876 (1999)

41.  Curtis S.W., Washburn T., Sewall C., DiAugustine R., Lindzey J., Couse J.F., Korach K.S.: Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc. Natl. Acad. Sci. USA 93: 12626-12630 (1996)

42.  Korach K.S., Couse J.F., Curtis S.W., Washburn T.F., Lindzey J., Kimbro K.S., Eddy E.M., Migiiaccio S., Snedeker S.M., Lubahn D.B., Schomberg D.W., Smith E.P.: Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Prog. Norm. Res. 51: 159-186 (1996)

43.  Krege J.H., Hodgin J.B., Couse J.F., Enmark E., Warner M., Mahler J.F., Sar M., Korach K.S., Gustafsson J.A., Smithies O.: Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc. Natl. Acad. Sci. USA 95: 15677-15682 (1998)

44.  Mosselman S., Polman J., Dijkema R.: ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 393: 49-53 (1996)

45.  Couse J.F., Lindzey J., Grandien K., Gustafsson J.A., Korach K.S.: Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 138: 4613-4621 (1997)

46.  Murphy L.C., Dotzlaw H., Leygue E., Coutts A., Watson P.: The pathophysiological role of estrogen receptor variants in human breast cancer. J. Steroid. Biochem. Mol. Biol. 65: 175-180(1998)

47.  Speirs V., Parkes A.T., Kerin M.J., Walton D.S., Carleton P.J., Fox J.N., Atkin S.L.: Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer? Cancer Res. 53: 525-528 (1999)

48.  Sun J., Meyers M.J., Fink B.E., Rajendran R., Katzenellenbogen J.A., Katzenellenbogen B.S.: Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 140: 800-804 (1999)

49.  Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., Scanlan T.S.: Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510(1997)

50.  Castoria G., Barone M.V., Di Domenico M., Bilancio A., Ametrano D., Migiiaccio A., Auricchio F.: Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBOJ 13: 2500-2510 (1999)

51.  Tora L., White J., Brou C., Tasset D., Webster N., Scheer E., Chambon P.: The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 53: 477-487 (1989)

52.  Katzenellenbogen B.S., Montano M.M., Ekena K., Herman M.E., Mclnerney E.M., William L.. McGuire Memorial Lecture: Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res. Treat. 44: 23-38 (1997)

53.  Howeil A., Dodwell D.J., Anderson H., Bedford J.: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann. Oncol. 3: 611-617 (1992)

54.  Tremblay G.B., Tremblay A., Copeland N.G., Gilbert D.J., Jenkins N.A., Labrie F., Giguere V.: Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol. 11: 353-365 (1997)

55.  Tremblay A., Tremblay G.B., Labrie C., Labrie F., Giguere V.: EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta. Endocrinology 139: 111-118 (1998)

56.  Webb P., Nguyen P., Valentine C., Lopez G.N., Kwok G.R., Mclnerney E., Katzenellenbogen B.S., Enmark E., Gustafsson J.A., Nilsson S., Kushner P.J.: The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol. Endocrinol. 13: 1672-1685 (1999)

57.  Beato M., Herrlich P., Schütz G.: Steroid hormone receptors: many actors in search of a plot, Cell 83: 851- 857 (1995)

58.  Takimoto G.S., Graham J.D., Jackson T.A., Tung L., Powell R.L., Horwitz L.D., Horwitz K.B.: Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J. Steroid. Biochem. Mol. Biol. 69: 45-50 (1999)

59.  Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom 0., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M.: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753- 758 (1997)

60.  Feng W,, Ribeiro R.C., Wagner R.L., Nguyen H., Apriletti J.W., Fletterick R.J., Baxter J.D., Kushner P.J., West B.L.: Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280: 1747-1749 (1998)

61.  Shiau A.K., Barstad D., Loria P.M., Cheng L, Kushner P.J., Agard D.A., Greene G.L.: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95: 927-937 (1998)

62.  Pike A.C., Brzozowski A.M., Hubbard R.E., Bonn T., Thorsell A.G., Engstrom O., Ljunggren J., Gustafsson J.A., Carlquist M.: Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 19: 4608-4618 (1999)

63.  Grese T.A., Sluka J.P., Bryant H.U., Cullinan G.J., Glasebrook A.L., Jones C.D., Matsumoto K., Palkowitz A.D., Sato M., Termine J.D., Winter M.A., Yang N.N., Dodge J.A.: Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. USA 94: 14105-14110 (1997)

64.  Deng T., Karin M.: c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature 371: 171-175 (1994)

65.  Treinies I., Paterson H.F., Hooper S., Wilson R., Mar-shall C.J.: Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-krnase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol. Cell. Biol. 19: 321-329 (1999)

66.  Altucci L., Addeo R., Cicatîello L., Dauvois S., Parker M.G., Truss M., Beato M., Sica V., Bresciani F., Weisz A.: 17beta-Estradioi induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogrene 13: 2315-2324 (1996)

67.  Kerkhoff E., Rapp U.R.: Cell cycle targets of Ras/Raf signalling. Oncogene 17: 1457-1462 (1998)

68.  Leone G., DeGregori J. Sears R., Jakoi L., Nevins J.R.: Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387: 422-426 (1997)

69.  Watts C.K., Brady A., Sarcevic B.p deFazio A., Musgrove E.A., Sutherland RL: Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol. 9: 1804-1813 (1995)

70.  Planas-Silva M.D., Weinberg R.A.: Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol. 17: 4059-4069 (1997)

71.  Muller D., Bouchard C., Rudolph B., Steiner P., Stuckmann I., Saffrich R., Ansorge W., Huttner W., Eilers M.: Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene 15: 2561-2576 (1997)

72.  Marsh K.L., Varley J.M.: Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry. Br. J. Cancer 77: 1460-1468 (1998)

73.  Porter P.L., Malone K.E., Heagerty P.J., Alexander G.M., Gatti L.A., Firpo E.J., Daling J.R., Roberts J.M.: Expression of cell-cycle regulators p27Ktp1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3: 222-225 (1997)

74.  Verbeek B.S., Vroom T.M., Adriaansen-Slot .SS., Ottenhoff-Kalff A.E., Geertzema J.G., Hennipman A., Rijksen G.: c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J. Pathol. 183: 383-388 (1996)

75.  Oft M., Pefi J., Rudaz C., Schwarz R, Beug R, Reichmann E.: TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 19: 2462-2477 (1996)

76.  Kretzschmar M., Doody J., Timokhina l., Massague J.: A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev. 13: 804-816 (1999)

77.  Dickson R.B., Lippman M.E.: Growth factors in breast cancer. Endocr. Rev. 19: 559-589 (1995)

78.  Harris A.L., Nicholson S., Sainsbury R., Wright C., Farndon J.: Epidermal growth factor receptor and other oncogenes as prognostic markers. J. Natl. Cancer Inst. Monogr. 11: 181-187(1992)

79.  Gullick W.J.: The c-erbB3/HER3 receptor in human cancer. Cancer Surv. 27: 339-349 (1996)

80.  Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W J., Stuart S.G., Udove J., Ullrich A., et al.:’ Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707- 712(1989)

81.  Baselga J., Norton L., Albanell J., Kim Y.M., Mendelsohn J.: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58: 2825-2831 (1998)

82.  Pietras R.J., Arboleda J., Reese D.M., Wongvipat N., Pegram M.D., Ramos L, Gorman C.M., Parker M.G., Sliwkowski M.X., Slamon D.J.: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446 (1995)

83.  Yu H., Levesque M.A., Khosravi M.J., Papanastasiou-Diamandi A., Clark G.M., Diamandis E.P.: Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br. J. Cancer 74: 1242-1247(1996)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr